Engineer. Selecting and curating pictures and videos trying to awaken your sense of wonder since 2014. For business partnerships: [email protected].
Italy, North by Northwest
Joined August 2010
- Tweets507K
- Following176
- Followers4.4M
- Likes12.1K
Massimo retweeted
An innovative preclinical approach is transforming the body's native immune cells into targeted oncological destroyers without requiring external laboratory manipulation. Researchers at MIT engineered specialized lipid nanoparticles to transport a messenger RNA payload directly to natural killer cells. While these innate cells naturally defend the body, the internal delivery of mRNA provides them with genetic programming to synthesize a specific chimeric antigen receptor. To ensure high selectivity, the outer surfaces of the nanoparticles are functionalized with specific antibody fragments that guide the delivery system directly to the receptors on the natural killer cells.
This localized in vivo engineering technique bypasses the logistical bottlenecks that limit current cellular immunotherapies. Conventional chimeric antigen receptor treatments require an expensive and time-consuming manufacturing workflow, where patient cells must be isolated, structurally altered, and cultivated ex vivo before being reintroduced. Directing this modification within the living organism simplifies the therapeutic pipeline, though definitive cost reductions and manufacturing efficiencies await confirmation in upcoming human clinical trials.
The therapeutic platform demonstrated high efficacy across several distinct animal paradigms. In a melanoma model, 60% of the treated mice achieved complete disease remission. Furthermore, the protocol completely eradicated malignancy in a separate T-cell lymphoma mouse model engrafted with human blood cells following five systematic nanoparticle administrations. Natural killer cells are uniquely suited for targeting T-cell malignancies because using engineered T cells to eradicate diseased T cells often results in severe fratricide, where the therapeutic cells aggressively neutralize each other.
The investigative team extended the utility of this technology to non-cancerous pathology by assessing its impact on autoimmune hepatitis, a state where aberrant T cells attack functional liver hepatocytes. A single nanoparticle injection selectively ablated these destructive, autoreactive T cells, allowing the damaged hepatic tissue to repair itself. While these versatile data highlight therapeutic potential spanning oncology and autoimmunity, the conclusions are based entirely on preclinical mouse models. Rigorous clinical evaluation is mandatory to verify the safety, therapeutic efficacy, and long-term durability of the system within human patients.
[Chen, Y., Monkovic, J., Mughal, H., et al. (2026). In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nature Biotechnology DOI: 10.1038/s41587-026-03310-1]
Massimo retweeted
In 1705, an Irish woman named Margorie McCall fell gravely ill with a fever in Lurgan, Ireland. Believing she had died, her family hastily buried her to prevent the spread of contagion. Her husband, John McCall, a local physician, had been unable to remove her valuable ring because her finger was badly swollen — a detail that soon attracted the attention of grave robbers.
That same night, body snatchers dug up the fresh grave. Unable to pull the ring from her finger, they began cutting it off. The sudden flow of blood shocked the still-living Marjorie out of her deep coma. She sat upright in the coffin and screamed, terrifying the robbers, who fled and reportedly never returned to their grim trade.
Covered in dirt and still wearing her burial clothes, Marjorie climbed out of the grave and walked home. When she knocked on the door, her husband John, still in mourning, jokingly remarked that if his wife were alive, he would swear it was her at the door. Upon opening it and seeing Marjorie standing before him — alive, bleeding, and in her shroud — he collapsed from shock and died on the spot.
John McCall was later buried in the grave originally dug for his wife.
Marjorie survived the ordeal, eventually remarried, and had several children. When she died many years later, she was laid to rest in Shankill Cemetery in Lurgan. Her headstone famously reads:
“Lived Once, Buried Twice.”
A pioneering clinical trial in the United Kingdom demonstrated that a single administration of psilocybin can induce full clinical remission in a substantial portion of individuals suffering from treatment-resistant depression. Initiated by investigators in London and guided by consultant psychiatrist James Rucker at the NIHR Maudsley Biomedical Research Centre, the randomized controlled study evaluated 60 adult participants whose depressive symptoms had failed to resolve using traditional pharmaceutical interventions.
The cohort was divided equally, with half of the subjects receiving a single dose of psilocybin, the active hallucinogenic compound isolated from psychedelic mushrooms, while the remaining half received a true inactive placebo. Crucially, both experimental arms were provided with an identical protocol of integrated psychological preparation and post-session integration therapy.
Three weeks following the intervention, 40% of the individuals assigned to the psilocybin group achieved complete symptom remission, characterized by a reduction in clinical scores to minimal baseline levels, whereas only 3% of the placebo group exhibited equivalent improvement. By the sixth week of observation, the overall therapeutic response rate within the psilocybin cohort expanded to 50%, maintaining a statistically significant efficacy margin over the control population.
Treatment-resistant major depressive disorder represents one of the most stubborn hurdles within modern psychiatry, frequently forcing patients to undergo multiple ineffective cycles of traditional selective serotonin reuptake inhibitors without experiencing substantial clinical relief. Notably, this investigation represents the first randomized, double-blind trial of psilocybin for depression to be fully funded by public resources in the UK, operating entirely within the National Health Service framework rather than a specialized private facility, a logistical detail that remains essential for evaluating how such protocols might scale to the general public. Reported adverse events were primarily categorized as mild and transient in nature.
Despite these encouraging outcomes, the trial featured a relatively small sample size, and the profound psychoactive nature of the compound made it highly probable that participants correctly deduced their specific group assignments, an unblinding effect that may have artificially widened the statistical variance between the cohorts.
Furthermore, the substance was administered under intense medical monitoring after extensive diagnostic screening, a protocol that differs fundamentally from unsupervised recreational usage. The research team is currently advocating for larger, multi-center, publicly funded clinical evaluations situated within broader community health frameworks, noting that standardized psilocybin-assisted therapies could eventually be incorporated directly into routine NHS treatment options.
[Rucker, J. J., Mantingh, T., Kerr-Gaffney, J., et al. (2026). Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public health setting: a randomized, double-blind, placebo-controlled trial. Nature Medicine, 32(8), 1954–1962. DOI: 10.1038/s41591-026-04541-0]
In 1705, an Irish woman named Margorie McCall fell gravely ill with a fever in Lurgan, Ireland. Believing she had died, her family hastily buried her to prevent the spread of contagion. Her husband, John McCall, a local physician, had been unable to remove her valuable ring because her finger was badly swollen — a detail that soon attracted the attention of grave robbers.
That same night, body snatchers dug up the fresh grave. Unable to pull the ring from her finger, they began cutting it off. The sudden flow of blood shocked the still-living Marjorie out of her deep coma. She sat upright in the coffin and screamed, terrifying the robbers, who fled and reportedly never returned to their grim trade.
Covered in dirt and still wearing her burial clothes, Marjorie climbed out of the grave and walked home. When she knocked on the door, her husband John, still in mourning, jokingly remarked that if his wife were alive, he would swear it was her at the door. Upon opening it and seeing Marjorie standing before him — alive, bleeding, and in her shroud — he collapsed from shock and died on the spot.
John McCall was later buried in the grave originally dug for his wife.
Marjorie survived the ordeal, eventually remarried, and had several children. When she died many years later, she was laid to rest in Shankill Cemetery in Lurgan. Her headstone famously reads:
“Lived Once, Buried Twice.”
Biomedical researchers successfully induced human cells sourced from individuals over the age of 50 to activate specific pluripotency genes within a single week. The resulting induced pluripotent stem cells satisfied rigorous diagnostic evaluations validating their physiological health and genomic structural integrity. This discovery marks a substantial leap in cellular reprogramming, a discipline where traditional engineering strategies spent nearly two decades attempting to optimize the efficiency of the biological pathways responsible for resetting cellular identity.
To achieve this breakthrough, OpenAI partnered with the longevity biotechnology firm Retro Biosciences to engineer a specialized foundation model designated as GPT-4b micro. This artificial intelligence architecture was trained heavily on expansive protein sequences and proteomic datasets rather than natural language. Designers utilized the model to entirely re-engineer two of the original Yamanaka factors, which are the famous core transcription factors that earned a Nobel Prize in 2012 for their ability to revert mature somatic cells into a pluripotent state. The synthetic variants produced by the model, named RetroSOX and RetroKLF, diverged from their wild-type ancestral sequences by an average of more than 100 amino acid residues. Despite these profound structural variations, the machine-designed proteins provoked over a 50-fold increase in the expression of crucial cellular reprogramming markers during laboratory screenings.
Historically, reverting specialized adult cells back into stem cells has been an exceptionally slow and highly inefficient process, regularly succeeding in fewer than 1 out of 1,000 targeted cells. This persistent barrier has severely restricted efforts to manufacture functional replacement tissues and to analyze how senescent cells might be biochemically rejuvenated. In addition to accelerating the overall timeline from several weeks down to just seven days, the newly engineered variants demonstrated an enhanced capability to facilitate DNA double-strand break repair within the host genome, indicating that their biological utility extends beyond simple conversion speed.
It is important to note that these experimental milestones were achieved entirely within in vitro laboratory cultures. Furthermore, the findings were disclosed directly via corporate technical announcements by OpenAI and Retro Biosciences rather than through a traditional, peer-reviewed scientific journal. Additionally, OpenAI Chief Executive Officer Sam Altman maintains a significant personal financial investment in Retro Biosciences. Nevertheless, this development serves as clear evidence that artificial intelligence can deliberately optimize core biological mechanisms, offering a robust new approach for automated tool design within regenerative medicine.
OpenAI & Retro Biosciences. (2025, August 22). Accelerating life sciences research. OpenAI]
Statistical modeling indicates that the probability of encountering an ideal romantic partner purely by chance is approximately 1 in 562. This calculation was developed by British mathematician and television broadcaster Rachel Riley, who evaluated data on behalf of the matchmaking platform eHarmony in 2017.
Working alongside researchers from the University of Bath, the team integrated 18 distinct socioeconomic and personal criteria that dictate romantic compatibility, encompassing specific age brackets, perceived physical attractiveness, current relationship status, and geographical search boundaries. Following the strict application of these multi-layered demographic filters, only roughly 84,000 individuals out of the entire adult population of the United Kingdom successfully fulfilled the average consumer requirements, producing the final probability metrics.
The mathematical outlook, however, varies significantly based on demographic variables and individual lifestyle habits. For instance, residents of London experienced superior baseline odds of 1 in 394 due to the sheer density of the local urban population. Furthermore, the likelihood of establishing a meaningful connection paradoxically improved alongside advancing age, shifting from an unfavorable 1 in 1,024 for individuals aged 18 to 24 up to a more favorable 1 in 304 for those within the 65 to 74 age group.
The probabilistic analysis ultimately concluded that small, deliberate behavioral modifications, including visiting fitness centers, expanding professional networks, widening geographic travel parameters, and utilizing online dating applications, all systematically shift the statistical distributions in favor of the individual.
[Walker-Arnott, E. The odds of finding love in London today are... Time Out London]
A preclinical discovery indicates that a specific strain of gut bacteria works in tandem with fasting cycles to activate cellular repair mechanisms prior to tissue injury. Investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 24-hour fasting period significantly elevates the concentration of a symbiotic gut bacterium, Akkermansia muciniphila, within the small intestine. This microbial population secretes a short-chain fatty acid metabolite known as propionate. Working in conjunction with the host metabolic shifts induced by food deprivation, propionate chemically alters histones to relax the structural packaging around epithelial DNA.
This epigenetic restructuring allows intestinal stem cells to preemptively transcribe genes linked to tissue regeneration. Consequently, when the intestinal lining subsequently sustains damage from radiation exposure, these pre-primed cells proliferate rapidly to accelerate structural restoration. Conversely, when the research team depleted this bacterial population using targeted antibiotics, the radioprotective benefits of fasting were entirely lost. Restoring the specific bacterial strain completely reinstated the protective effect.
Radiation oncology treatments targeting abdominal or pelvic malignancies frequently cause collateral damage to the highly sensitive mucosal architecture of the small intestine, triggering severe gastrointestinal side effects and occasionally forcing clinicians to limit therapeutic radiation doses. Because strict fasting protocols are frequently impractical or unsafe for oncological patients undergoing active treatment, the investigators hope that therapeutic administration of either Akkermansia muciniphila or its primary metabolite, propionate, could eventually mirror these protective benefits without requiring dietary restriction.
Nevertheless, because these findings are derived from a preclinical animal study, it remains unknown whether an identical microbial mechanism occurs in human subjects or if it can safely enhance clinical outcomes during clinical radiotherapy. Despite these translational limitations, the study identifies a clear, accessible biological lever via native gut microbes to protect healthy tissue during cancer care. Moving forward, the investigators plan to explore whether this microbial priming network can be leveraged to safeguard other rapidly dividing tissues, such as bone marrow.
[Chen, H., et al. (2026). Fasting primes small intestinal regeneration after damage via Akkermansia muciniphila-produced propionate. Proceedings of the National Academy of Sciences, 123(28), e2529215123. DOI: 10.1073/pnas.2529215123]
